Newron Pharmaceuticals to Webcast Presentations from 2018 R&D Day Event on October 31
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system, will webcast the presentations from its 2018 Research and Development Day in New York City on Wednesday, October 31, 2018 beginning at 10:00 AM EDT.
Media and investors may access the live video webcast directly at https://livestream.com/Convene/Newron2018 beginning at 10:00 AM EDT.
This research and investor update event will feature presentations from Newron’s senior executive management team as well as two of the leading clinicians in the fields of schizophrenia and Rett syndrome, John Kane, MD, Professor and Chairman of the Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Daniel Glaze, MD, Neurologist and Professor at Baylor College of Medicine in Houston, Texas.
Institutional investors, analysts and media representatives interested in attending the event in New York can email firstname.lastname@example.org to register and to receive additional details. Please note that pre-registration is required to attend in person.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system. The company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005446/en/